Mostrar el registro sencillo

dc.contributor.authorFernández de Larrea, Carlos
dc.contributor.authorKyle, Robert
dc.contributor.authorRosiñol, Laura
dc.contributor.authorPaiva, Bruno
dc.contributor.authorEngelhardt, Monika
dc.contributor.authorUsmani, Saad
dc.contributor.authorCaers, Jo
dc.contributor.authorGonsalves, Wilson
dc.contributor.authorSchjesvold, Fredrik
dc.contributor.authorMerlini, Giampaolo
dc.contributor.authorLentzch, Suzanne
dc.contributor.authorOcio San Miguel, Enrique María 
dc.contributor.authorGarderet, Laurent
dc.contributor.authorMoreau, Philippe
dc.contributor.authorSonneveld, Pieter
dc.contributor.authorBadros, Ashraf
dc.contributor.authorGahrton, Gösta
dc.contributor.authorGoldschmidt, Hartmut
dc.contributor.authorTuchman, Sascha
dc.contributor.authorEinsele, Hermann
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-02-01T17:25:59Z
dc.date.available2022-02-01T17:25:59Z
dc.date.issued2021
dc.identifier.issn2044-5385
dc.identifier.urihttp://hdl.handle.net/10902/23827
dc.description.abstractPrimary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ?5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.es_ES
dc.description.sponsorshipFunding: This work has been supported in part by grants from the Instituto de Salud Carlos III, Spanish Ministry of Health (FIS PI19/00669), Fondo Europeo de Desarrollo Regional (FEDER) and 2017SGR00792 (AGAUR; Generalitat de Catalunya).es_ES
dc.format.extent5 p.es_ES
dc.language.isoenges_ES
dc.publisherNature Pub. Groupes_ES
dc.rightsAttribution 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBlood Cancer J . 2021 Dec 2;11(12):192es_ES
dc.titlePrimary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentagees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://www.doi.org/10.1038/s41408-021-00587-0es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1038/s41408-021-00587-0
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International